天士力之骄专利组合分析及对中成药企业专利组合构建的启示OA
Analysis of Tasly-Zhijiao's Patent Portfolio and Its Implications for the Construction of Patent Portfolios by Traditional Chinese Medicinal Products Enterprises
目的:研究天士力之骄专利组合,为我国中成药企业专利布局提供参考.方法:以"天津天士力之骄药业有限公司"为当前申请人,在PatSnap数据库中进行检索,分析专利基本信息、专利技术主题、专利具体内容、专利组成来源,并且以注射用益气复脉为例,分析专利组合策略.结果:共检索到132件专利,其中,发明专利130件,授权率为87%.79件授权发明已失效,失效专利维持时间多在15年及以上,99%的失效原因为未缴纳年费.技术主题以方法专利为主,专利组合来源包括自主研发以及专利转移,保护内容以中成药专利为主、中药为辅.结论:我国中成药企业在构建专利组合时,应提高发明专利占比,完善专利类型,以不同中成药具有相同的药物组成为纽带,提高专利组合稳定性,采用多样化的方式扩宽专利组合.
Objective:To investigate the patent portfolio of Tianjin Tasly ZhiJiao Pharmaceutica Co.,Ltd.,providing strategic references for traditional Chinese patent medicine(TCPM)enterprises in China.Methods:Patents were re-trieved from the PatSnap database using"Tianjin Tasly ZhiJiao Pharmaceutical Co.,Ltd."as the current applicant.Analysis encompassed:basic patent information,technology themes,substantive content,and portfolio sources.The patent strategy was further examined using Yiqi Fumai Injection as a case study.Results:132 patents were identified,including 130 invention patents(87%grant rate).Among granted inventions,79 were invalidated-primarily due to a nnuity non-payment(99%),with most maintaining validity for≥15 years.Technology themes were dominated by process patents.Portfolio sources included independent R&D and patent transfers,with protection focusing on TCPM formulations rather than Chinese materia medica.Conclusion:TCPM enterprises should increase invention patent rati-os,diversify patent types,enhance portfolio stability by linking formulations sharing identical active compositions,and expand portfolios through multifaceted approaches.
甄思圆;刘扬;梁谦;李平;贺帆;李海燕
天津市中医药研究院,天津 300120中国中医科学院 中医药信息研究所,北京 100700天津市中医药研究院,天津 300120天津市中医药研究院,天津 300120天津市中医药研究院,天津 300120中国中医科学院 中医药信息研究所,北京 100700
医药卫生
中成药专利组合天士力之骄
Chinese Patent MedicinePatent PortfolioTasly-Zhijiao
《亚太传统医药》 2026 (2)
8-11,4
首都卫生发展科研专项(首发2022-1-4291)中国中医科学院科技创新工程(CI2021A00501)
评论